---

---

treatment   source : Www.globenewswire.com   

save search

---

California Water Service Group Moving Forward to Install PFAS Treatment Despite CPUC Dismissal of Request to Track Capital Costs in Pre-Approved Memorandum Account
Published: 2024-04-18 (Crawled : 21:00) - globenewswire.com
CWT | $45.79 1.98% 0.0% 710K |

Utilities

| 3.11% | O: 0.9% H: 2.19% C: 2.19%
water california service group treatment

---

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K |

Health Technology

| Email alert Add to watchlist
onct-534 first cancer treatment for study

---

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K |

Wholesale Trade

| -11.61% | O: 2.68% H: 3.48% C: -11.3%
treatment biopharma royalties global for agreement

---

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K |

Health Technology

| -26.81% | O: 3.47% H: 0.0% C: -3.66%
precision treatment

---

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K |

n/a

| -2.46% | O: -0.82% H: 0.0% C: 0.0%
disorders treatment for agreement

---

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 1.66% | O: 0.87% H: 0.16% C: -0.59%
kesimpta sclerosis novartis show benefits

---

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M |

| Email alert Add to watchlist
au8 neurology sclerosis treatment for meeting

---

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $11.995 -0.62% -0.63% 87K |

| 1.05% | O: 5.32% H: 0.0% C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy

---

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K |

n/a

| -5.54% | O: 1.15% H: 1.03% C: -1.45%
disease treatment for meeting therapeutics

---

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K |

Health Technology

| -15.13% | O: -10.79% H: 0.0% C: -3.75%
gtx-102 positive treatment

---

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
EGRX | $4.63 3.35% 3.24% 60K |

Health Technology

| -3.76% | O: -8.14% H: 19.55% C: 18.18%
conference treatment pharmaceuticals for trial response

---

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Published: 2024-04-11 (Crawled : 14:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K |

Health Technology

| -10.75% | O: -1.08% H: 1.63% C: -2.72%
first solution light treatment for study

---

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K |

| 1.37% | O: 25.49% H: 23.75% C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics

---

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -0.22% | O: 0.32% H: 0.04% C: -0.56%
ARVN | $34.78 1.43% 1.41% 940K |

Health Technology

| -3.9% | O: 8.28% H: 0.56% C: -4.75%
arv-766 protac license cancer treatment global protein for commercialization agreement

---

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -13.06% | O: 4.9% H: 6.03% C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical

---

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Published: 2024-04-10 (Crawled : 20:00) - globenewswire.com
CLLS | $2.47 0.4% 12K |

Health Technology

| -8.6% | O: 0.72% H: 1.6% C: -0.36%
metabolic treatment for

---

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K |

Health Technology

| 67.83% | O: 123.48% H: 0.0% C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential

---

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K |

Health Technology

| -10.17% | O: 1.18% H: 4.28% C: 1.17%
publication treatment

---

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K |

n/a

| -9.85% | O: -3.03% H: 7.03% C: -0.78%
patent disorders treatment for application

---

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M |

Health Technology

| -21.71% | O: 0.57% H: 11.65% C: 4.55%
disease control treatment trial therapeutics

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---